| 摘要 |
PROBLEM TO BE SOLVED: To provide highly purified omega-3 fatty acid formulations having an ideal EPA:DHA ratio for treatment of a broad range of cardiovascular, autoimmune, inflammatory, and central nervous system disorders.SOLUTION: The invention provides pharmaceutical formulations comprising EPA and DHA in a weight to weight ratio from about 3.5:1 to about 6.99:1. It is preferred that the formulations contain, as a unit dosage form, at least 50 mg of DHA and at least 300 mg of EPA and in which the content of EPA and DHA in total amount is greater than 84% of the formulation by weight, and the omega-3 fatty acids in total amount is greater than 90% of the formulation by weight respectively. As for the formulation, it is preferred to be provided in form of capsules, such as a gelatin capsule. |
